Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Beam Therapeutics (BEAM) Stock Price & Analysis
1,158 Followers
BEAM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.95 - $49.50
Previous Close$24.84
Volume436.54K
Average Volume (3M)1.47M
Market Cap
$2.08B
Enterprise Value$1.12B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$168.12M
Price to Earnings (P/E)-13.9
Beta1.95
Next Earnings
Aug 06, 2024EPS Estimate
-$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding82,311,067
10 Day Avg. Volume1,154,778
30 Day Avg. Volume1,465,653
Standard Deviation0.27
R-Squared0.15
Alpha0.00641
Financial Highlights & Ratios
Price to Book (P/B)2.22
Price to Sales (P/S)275.93
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit2.96
Enterprise Value/Ebitda-9.00
Forecast
1Y Price Target
$46.67Price Target Upside84.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Beam Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCompletion of dosing and engraftment for patients in the BEACON trial of BEAM-101 shows progress in the company's pipeline.
Financial StabilityThe company's strong cash position is expected to fund multiple pipeline developments, providing financial stability.
Pipeline AdvancementPlanned initiation of Phase 1 study for BEAM-302 and IND submission for BEAM-301 demonstrate a growing and advancing pipeline.
Bears Say
Clinical Trial SetbacksVERV has paused enrollment in the Phase 1b Heart-1 trial due to safety concerns.
Financial PerformanceFor 4Q23, operating expenses were higher than expectations, signaling potential concerns over financial management.
Partnership DelaysPotential milestone payments from LLY to BEAM have been delayed due to the VERVE-101 trial pause.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $16.95 and its highest was $49.50 in the past 12 months.
What is Beam Therapeutics’s market cap?
Currently, no data Available
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 77 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on May 07, 2024. The company reported -$1.21 earnings per share for the quarter, beating the consensus estimate of -$1.415 by $0.205.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -$1.14.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 82,311,066 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.21 in its last earnings report, beating expectations of -$1.415. Following the earnings report the stock price went down -1.097%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Among the largest hedge funds holding Beam Therapeutics’s share is ARK Investment Management LLC. It holds Beam Therapeutics’s shares valued at 270M.
---
Beam Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$46.67 (84.47% Upside)
$46.67 (84.47% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 809.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.08%
12-Months-Change
Fundamentals
Return on Equity
-16.09%
Trailing 12-Months
Asset Growth
2.06%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
---
BEAM Stock 12 Month Forecast
Average Price Target
$46.67
▲(84.47% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Best Analysts Covering BEAM
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
-6.32%
reiterated a buy rating 15 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -6.32% per trade.
---